Editorial & Advertiser disclosure
Global Banking & Finance Review® is an online platform offering news, analysis, and opinion on the latest trends, developments, and innovations in the banking and finance industry worldwide. The platform covers a diverse range of topics, including banking, insurance, investment, wealth management, fintech, and regulatory issues. The website publishes news, press releases, opinion and advertorials on various financial organizations, products and services which are commissioned from various Companies, Organizations, PR agencies, Bloggers etc. These commissioned articles are commercial in nature. This is not to be considered as financial advice and should be considered only for information purposes. It does not reflect the views or opinion of our website and is not to be considered an endorsement or a recommendation. We cannot guarantee the accuracy or applicability of any information provided with respect to your individual or personal circumstances. Please seek Professional advice from a qualified professional before making any financial decisions. We link to various third-party websites, affiliate sales networks, and to our advertising partners websites. When you view or click on certain links available on our articles, our partners may compensate us for displaying the content to you or make a purchase or fill a form. This will not incur any additional charges to you. To make things simpler for you to identity or distinguish advertised or sponsored articles or links, you may consider all articles or links hosted on our site as a commercial article placement. We will not be responsible for any loss you may suffer as a result of any omission or inaccuracy on the website.
Published by Global Banking & Finance Review®
Posted on February 18, 2026
1 min read
Last updated: February 18, 2026
Overview of the Licensing Agreement
Feb 18 (Reuters) – Unnatural Products said on Wednesday it has signed a licensing agreement with Novartis to develop macrocyclic peptide-based therapies for a cardiovascular program.
The California-based biotech company will receive up to $100 million in upfront payment and as much as $1.7 billion in development, regulatory, and commercial milestones. It will also be eligible for tiered royalties mid-single up to low double-digits on annual net sales.
The Swiss drugmaker will take the lead to oversee clinical development, manufacturing and global commercialization of any resulting drugs.
Details of the Financial Agreement
The company did not disclose the exact nature of the program.
Understanding Macrocyclic Peptides
Macrocyclic peptides are a class of therapeutic molecules shaped into a ring-like structure, which gives them advantages over traditional small-molecule drugs and larger biologics.
(Reporting by Siddhi Mahatole in Bengaluru; Editing by Mrigank Dhaniwala)